×

CareDx to Present at Upcoming Investor Conferences

BRISBANE, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that Peter Maag, PhD, CEO and President, and Ken Ludlum, Chief Financial Officer, will be presenting at the following upcoming investor conferences:

  • The 2015 Leerink Global Healthcare Conference in New York City on February 11, 2015 at 7:40am PT/10:40am ET.
  • The 36th Annual Raymond James Institutional Investors Conference in Orlando, Florida on March 1-4, 2015 (presentation date and time to be announced on Company website).
  • The 27th Annual ROTH Conference in Dana Point, CA on March 8-11, 2015 (presentation date and time to be announced on Company website).

A live audio webcast of these presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of the presentation will begin approximately one hour after the conclusion of each of the live presentations and will be available on the Company's website for 90 days from the date of the event.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing to detect donor-derived cell free DNA to monitor the health of organs after transplantation. The Company is currently investigating a research use only donor-derived cell free DNA-based test for heart transplant recipients. For more information, please visit: www.CareDxInc.com.

CONTACT: Westwicke Partners, LLC Leigh J. Salvo Principal Tel: 415-513-1281 leigh.salvo@westwicke.com

Source:CareDx, Inc.